ATE366744T1 - Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen - Google Patents

Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen

Info

Publication number
ATE366744T1
ATE366744T1 AT98108855T AT98108855T ATE366744T1 AT E366744 T1 ATE366744 T1 AT E366744T1 AT 98108855 T AT98108855 T AT 98108855T AT 98108855 T AT98108855 T AT 98108855T AT E366744 T1 ATE366744 T1 AT E366744T1
Authority
AT
Austria
Prior art keywords
protein
receptor activity
receptor
compound
linked
Prior art date
Application number
AT98108855T
Other languages
English (en)
Inventor
Stephen Brian Henry Kent
Raymond Cecil Delisle Milton
Saskia Charlotte Floren Milton
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25403558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366744(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE366744T1 publication Critical patent/ATE366744T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
AT98108855T 1992-06-05 1993-06-07 Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen ATE366744T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89481792A 1992-06-05 1992-06-05

Publications (1)

Publication Number Publication Date
ATE366744T1 true ATE366744T1 (de) 2007-08-15

Family

ID=25403558

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98108855T ATE366744T1 (de) 1992-06-05 1993-06-07 Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen
AT93916447T ATE178650T1 (de) 1992-06-05 1993-06-07 D-enzymzusammensetzungen und verfahren zu deren verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93916447T ATE178650T1 (de) 1992-06-05 1993-06-07 D-enzymzusammensetzungen und verfahren zu deren verwendung

Country Status (9)

Country Link
US (5) US6548279B1 (de)
EP (2) EP0882737B1 (de)
JP (2) JPH08501207A (de)
AT (2) ATE366744T1 (de)
AU (2) AU678768B2 (de)
CA (1) CA2137378C (de)
DE (2) DE69334152T2 (de)
ES (1) ES2290976T3 (de)
WO (1) WO1993025667A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE366744T1 (de) * 1992-06-05 2007-08-15 Scripps Research Inst Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
ATE377006T1 (de) * 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
BR0012660A (pt) 1999-07-22 2002-04-09 Procter & Gamble Variante de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
CN1373802A (zh) 1999-07-22 2002-10-09 宝洁公司 在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体
MXPA02000842A (es) 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
IL150291A0 (en) * 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
US20030170846A1 (en) * 2000-04-24 2003-09-11 Weisgerber David John Enzyme variants having one or more D-amino acid substitutions
US20050181464A1 (en) * 2002-04-04 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
US7588575B2 (en) * 2003-10-21 2009-09-15 Innovative Spinal Technologies Extension for use with stabilization systems for internal structures
EP2324048A2 (de) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Vegf-bindende peptidtherapeutika und verfahren zu ihrer verwendung
EP2638063A4 (de) 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc Gb1-peptid-bibliotheken und -verbindungen sowie screening-verfahren dafür
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
WO2013082531A2 (en) 2011-12-02 2013-06-06 Reflexion Pharmaceuticals Broad spectrum influenza a neutralizing vaccines and d-peptidic compounds, and methods for making and using the same
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
WO2014140882A2 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
AU2016260274A1 (en) * 2015-05-11 2017-10-12 Shiseido Company, Ltd. Chiral analysis method and chiral analysis system for bound-type amino acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790240A (fr) 1971-10-19 1973-02-15 Sumitomo Chemical Co Procede de preparation de l'acide mixte (+)-cis, (+)-trans- chrysanthemique
US3963573A (en) 1975-03-03 1976-06-15 The Procter & Gamble Company Process for producing N-acyl-L-methionine
US4151198A (en) 1978-06-02 1979-04-24 American Cyanamid Company Resolution of N-acyl-DL (+)-phenylalanines
FR2443452A1 (fr) 1978-12-08 1980-07-04 Roussel Uclaf Nouveau procede de dedoublement de l'acide dl cis et dl trans chrysanthemique
US4262092A (en) 1979-05-08 1981-04-14 Ethyl Corporation Process for producing N-acyl-D-phenylalanine ester
US4290893A (en) 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4454344A (en) 1982-08-23 1984-06-12 American Cyanamid Company Method for the resolution of racemic 2-(p-difluoromethoxyphenyl)-3-methylbutyric acid
US5157019A (en) * 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US5066716A (en) * 1988-12-13 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US5098836A (en) * 1989-08-14 1992-03-24 Phillips Petroleum Company Deoxygenation in field preparation of polymers in aqueous solution
US5585353A (en) * 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
AU668347B2 (en) * 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
DK0635025T3 (da) * 1992-04-07 2003-01-27 Scripps Research Inst Fremgangsmåde til fremstilling af modificerede proteiner
ATE366744T1 (de) * 1992-06-05 2007-08-15 Scripps Research Inst Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor

Also Published As

Publication number Publication date
US7118856B2 (en) 2006-10-10
DE69324362D1 (de) 1999-05-12
US5910437A (en) 1999-06-08
ES2290976T3 (es) 2008-02-16
US20030113881A1 (en) 2003-06-19
CA2137378A1 (en) 1993-12-23
AU3756497A (en) 1997-12-18
DE69334152D1 (de) 2007-08-23
DE69334152T2 (de) 2008-03-13
US6040133A (en) 2000-03-21
JP4312615B2 (ja) 2009-08-12
EP0647266B1 (de) 1999-04-07
AU721228B2 (en) 2000-06-29
CA2137378C (en) 2008-08-05
JPH08501207A (ja) 1996-02-13
JP2004275180A (ja) 2004-10-07
EP0882737B1 (de) 2007-07-11
US6548279B1 (en) 2003-04-15
US7135279B2 (en) 2006-11-14
WO1993025667A1 (en) 1993-12-23
EP0647266A1 (de) 1995-04-12
AU4599693A (en) 1994-01-04
ATE178650T1 (de) 1999-04-15
EP0882737A1 (de) 1998-12-09
US20040086988A1 (en) 2004-05-06
AU678768B2 (en) 1997-06-12
DE69324362T2 (de) 1999-08-26

Similar Documents

Publication Publication Date Title
ATE366744T1 (de) Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen
DE68926991D1 (de) Verfahren zum Nachweis und zur Identifizierung von Nukleinsäure enthaltenden Teilen
DE59403519D1 (de) Verfahren zur Rückgewinnung von fluorierten Carbonsäuren
DE69212011D1 (de) Endothelin Antagoniste
DE10199015I1 (de) Mitteln zur Modulierung von Verfahren durch retinoid Rezeptoren und dafuer nuetzliche Verbindungen
DE69411268D1 (de) Verfahren zur schnellen quantifizierung von microorganismenwachstum
DE69309485D1 (de) Verfahren zur verteilung von schnittstellenzeigern fur fernprozeduranrufe
DE69935502D1 (de) Synthetische polymere und verfahren, kits oder zusammenstellungen zur modulation deren löslichkeit
ATE141588T1 (de) Polymerisationsinhibitoren für acrylsäure und ester
DE69433357D1 (de) Rekombinantes Mersacidin und Verfahren zu seiner Herstellung
DE69129115D1 (de) Neues verfahren zur behandlung von depression
ATE240305T1 (de) Verfahren zur herstellung von 2- hydroxybenzamidderivaten
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE191448T1 (de) Verfahren zur kontinuierlichen carbonylierung von olefinen
ATE194014T1 (de) Verfahren zur reinigung von teppichen
ATE41162T1 (de) Verfahren zur herstellung von insulin-derivaten.
ATE125247T1 (de) Verfahren zur reinigung von carbonsäuren.
ATE374210T1 (de) Verfahren zur identifikation von modulatoren von hif-1-alpha
DE69318559D1 (de) Peptide brauchbar als microsequezierungsstandard und verfahren zu ihrer anwendung
ATE43570T1 (de) Verfahren zur racemisierung optisch aktiver aminosaeuren.
ATE245670T1 (de) Verfahren zur kettenverlängerung von alpha,omega- dihydroxypoly(diorganosiloxanen) und vernetzbare mischungen, enthaltend kettenverlängerte alpha, omega-dihydroxypoly(diorganosiloxane)
DE69607653D1 (de) Verfahren zur carbonylierung von ungesättigten acetylenverbindungen
DE69409651D1 (de) Verfahren zur carbonylierung von acetylenisch ungesättigten verbindungen
ATE109468T1 (de) Verbindungen zur einführung einer sh-gruppe in tyrosin.
ATE241016T1 (de) Verbessertes verfahren zur bestimmung von lipase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties